Abstract
The author report clinical experience with 212 cases of mammary cancer metastatic to bone, in 186 of which radiotherapy was given, and in 26 steroid hormone therapy.
At least 70 per cent of patients with bone metastasis from breast cancer were relieved of pain by adequate roentgen therapy, the relief lasting for most of the survival time in many instances.
About 25 per cent of patients had recalcification or reossification of bony lesions with roentgen therapy; while dramatic, this is not always an indication that relief of pain will continue or that survival time will be lengthened.
If and when adequate radiotherapy has not been effective or cannot be administered (for example, in a patient with extremely widespread metastasis, or one residing at a considerable distance from radiotherapeutic service) steroid hormone therapy in adequate dosage is frequently beneficial. From 40 per cent to 75 per cent of patients with bone metastases from breast cancer are relieved of pain by steroid hormone therapy. In about 15 per cent of cases recalcification of the lesion occurs.
Effective roentgen therapy may usually be given in a relatively brief period of time (one to two weeks). Effective steroid hormone therapy usually requires from 12 to 24 weeks.
Complications of steroid hormone therapy are numerous. Some patients are made considerably worse by such therapy. These complications may only be controlled by reduction or discontinuation of the hormones. For this reason, it is recommended that irradiation always be used as the initial method of palliation.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- ABRAMS H. L., SPIRO R., GOLDSTEIN N. Metastases in carcinoma; analysis of 1000 autopsied cases. Cancer. 1950 Jan;3(1):74–85. doi: 10.1002/1097-0142(1950)3:1<74::aid-cncr2820030111>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
- ANDERSEN P. E. Testosterone propionate in the treatment of advanced carcinoma of the breast. Acta radiol. 1949 Sep 30;32(2-3):159–168. doi: 10.3109/00016924909138782. [DOI] [PubMed] [Google Scholar]
- FRIEDELL H. L., STORAASLI J. P. The use of radioactive phosphorus in the treatment of carcinoma of the breast with widespread metastases to bone. Am J Roentgenol Radium Ther. 1950 Oct;64(4):559–575. [PubMed] [Google Scholar]
- GARLAND L. H., BAKER M., PICARD W. H., Jr, SISSON M. A. Roentgen and steroid hormone therapy in mammary cancer metastatic to bone. J Am Med Assoc. 1950 Nov 18;144(12):997–1004. doi: 10.1001/jama.1950.62920120003008. [DOI] [PubMed] [Google Scholar]
- HOMBURGER F., KASDON S. C., FISHMAN W. H. Methylandrostenediol: a non-virilizing derivative of testosterone in metastatic cancer of the breast. Proc Soc Exp Biol Med. 1950 May;74(1):162–164. doi: 10.3181/00379727-74-17840. [DOI] [PubMed] [Google Scholar]
- KARNOFSKY D. A., BURCHENAL J. H. Present status of clinical cancer chemotherapy. Am J Med. 1950 Jun;8(6):767–788. doi: 10.1016/0002-9343(50)90102-1. [DOI] [PubMed] [Google Scholar]
- Lenz M., Freid J. R. METASTASES TO THE SKELETON, BRAIN AND SPINAL CORD FROM CANCER OF THE BREAST AND THE EFFECT OF RADIOTHERAPY. Ann Surg. 1931 Jan;93(1):278–293. doi: 10.1097/00000658-193101000-00036. [DOI] [PMC free article] [PubMed] [Google Scholar]
- SWYER A. J., BERGER J. S., GORDON H. M., LASZLO D. Hypercalcemia in osteolytic metastatic cancer of the breast. Am J Med. 1950 Jun;8(6):724–732. doi: 10.1016/0002-9343(50)90096-9. [DOI] [PubMed] [Google Scholar]
- TAYLOR S. G., 3rd, AYER J. P., MORRIS R. S., Jr Cortical steroids in treatment of cancer; observations on effects of pituitary adrenocorticotropic hormone (ACTH) and cortisone in far advanced cases. J Am Med Assoc. 1950 Nov 25;144(13):1058–1064. doi: 10.1001/jama.1950.02920130010003. [DOI] [PubMed] [Google Scholar]